Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rejuvant is a longevity-focused biotechnology company, officially operating as Ponce de Leon Health, that develops science-backed nutraceuticals to extend human healthspan. The company's flagship product, Rejuvant LifeTabs, utilizes a patented, sustained-release formulation of Calcium Alpha-Ketoglutarate (LifeAKG) to target fundamental biological aging processes. Developed in partnership with the Buck Institute for Research on Aging, Rejuvant aims to modulate the mTOR pathway, reduce systemic inflammation, and optimize DNA methylation patterns. Clinical research, including a published retrospective study, has demonstrated the product's ability to reduce biological age by an average of eight years as measured by epigenetic clocks. Rejuvant provides a comprehensive longevity solution by pairing its supplements with non-invasive DNA methylation testing to track consumer progress.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rejuvant.